Figure 5.

Extended mutation profiling improves risk stratification. (a) Risk stratification of patients was performed according to the ELN-2017 criteria, before (−) and after (+) incorporating the extended mutation profiling data obtained by high-throughput sequencing (NGS). Due to the lack of information on the FLT3-ITD allelic burden, two additional groups were considered: favorable|intermediate and intermediate|adverse. (b) Kaplan–Meier curves for the overall survival of patients classified as adverse risk irrespective of data obtained by high-throughput sequencing (NGS no), and patients reclassified as adverse risk because high-throughput sequencing identified mutations in the ASXL1, RUNX1, and TP53 genes (NGS yes).